Lecap Asset Management Ltd. Acquires 2,412 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Lecap Asset Management Ltd. grew its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 42.6% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 8,072 shares of the company’s stock after buying an additional 2,412 shares during the quarter. Lecap Asset Management Ltd.’s holdings in Neurocrine Biosciences were worth $930,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the company. 1832 Asset Management L.P. boosted its stake in shares of Neurocrine Biosciences by 1,370.7% during the 2nd quarter. 1832 Asset Management L.P. now owns 541,200 shares of the company’s stock worth $74,507,000 after acquiring an additional 504,400 shares during the period. AQR Capital Management LLC raised its position in Neurocrine Biosciences by 23.0% during the second quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company’s stock valued at $166,959,000 after purchasing an additional 228,444 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Neurocrine Biosciences by 2.3% during the 1st quarter. Vanguard Group Inc. now owns 9,930,926 shares of the company’s stock worth $1,369,673,000 after buying an additional 220,598 shares in the last quarter. Iron Triangle Partners LP bought a new position in shares of Neurocrine Biosciences in the first quarter worth about $30,342,000. Finally, Renaissance Technologies LLC boosted its position in Neurocrine Biosciences by 9.6% in the second quarter. Renaissance Technologies LLC now owns 2,468,146 shares of the company’s stock valued at $339,790,000 after buying an additional 216,500 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock opened at $115.08 on Thursday. Neurocrine Biosciences, Inc. has a fifty-two week low of $103.63 and a fifty-two week high of $157.98. The company has a market capitalization of $11.58 billion, a PE ratio of 31.70 and a beta of 0.36. The company has a 50 day moving average price of $124.09 and a 200-day moving average price of $134.34.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Thursday, August 1st. The company reported $0.63 EPS for the quarter, missing the consensus estimate of $1.15 by ($0.52). Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. The business had revenue of $590.20 million during the quarter, compared to the consensus estimate of $545.98 million. During the same quarter in the prior year, the firm posted $0.95 EPS. The company’s revenue for the quarter was up 30.4% compared to the same quarter last year. On average, analysts forecast that Neurocrine Biosciences, Inc. will post 4.19 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Ingrid Delaet sold 273 shares of the firm’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $147.70, for a total value of $40,322.10. Following the completion of the sale, the insider now owns 6,607 shares of the company’s stock, valued at $975,853.90. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Julie Cooke sold 12,632 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $153.26, for a total value of $1,935,980.32. Following the transaction, the insider now directly owns 18,202 shares of the company’s stock, valued at approximately $2,789,638.52. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ingrid Delaet sold 273 shares of the firm’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $147.70, for a total transaction of $40,322.10. Following the transaction, the insider now directly owns 6,607 shares of the company’s stock, valued at $975,853.90. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 59,968 shares of company stock worth $8,999,632 in the last 90 days. 4.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

NBIX has been the subject of several analyst reports. Robert W. Baird raised their target price on Neurocrine Biosciences from $157.00 to $180.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. HC Wainwright restated a “buy” rating and set a $190.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, August 29th. Royal Bank of Canada dropped their price target on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating on the stock in a research report on Friday, October 4th. JPMorgan Chase & Co. upped their target price on shares of Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Finally, BMO Capital Markets cut their price objective on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a research report on Thursday, October 17th. Five analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $163.91.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.